Director of Clinical Research

Danville, Pennsylvania (US)
Competitive salary and benefits
Apr 25, 2018
Jun 26, 2018
Career Fair Category
Career Fair

Director of Clinical Research

Geisinger Cancer Institute – Pennsylvania

Geisinger is currently seeking BC Hematologist/Oncologist for a leadership position with a well-established research program and practice at Geisinger Medical Center, located in Danville, PA.

This position requires experience and leadership in clinical oncology research.   In addition to inpatient and outpatient clinical responsibilities, the director will lead Geisinger’s NCI Community Oncology Research Program (NCORP) Community Site network and other research activities including, but not limited to, industry sponsored, investigator initiated, and innovative cancer care delivery. The research program spans the health system service area and is established on five hospital campuses and extends to four additional community clinic locations.    As Director of Clinical Research, they will be responsible for the research portfolio of the cancer programs; partnerships and strategic planning; and investigator oversight and mentoring. The director will apply leadership skills and engage associates across multiple disciplines to further the research program in areas that include cancer care delivery research and cancer genomics through Geisinger’s MyCode project.

Please forward CV and letter of interest to:  Rajiv Panikkar, MD, Chair, Geisinger Cancer Institute, c/o Julie Dent, Talent Management,

**Does not qualify for J-1 waiver. We are an Affirmative Action, Equal Opportunity Employer.

Geisinger serves nearly three million residents in central, western and northeastern Pennsylvania through a network of 13 integrated hospitals campuses, community practice clinics, and a 1,600 multi-specialty physician group. Geisinger has been nationally recognized for innovation, quality care, research and medical teaching. Our more than 30-year alliance with the National Cancer Institute (NCI) and its community research programs allows us to offer the most advanced care and treatment options to patients close to home. Geisinger is a community site in the new NCI Community Oncology Research Program (NCORP).

MyCode® Community Health Initiative has consented more than 112,000 Geisinger patients who will provide blood and/or tissue samples to be genetically sequenced. That data will be combined with each participant's medical record to provide Geisinger researchers with information to investigate new approaches to disease control, diagnosis and treatment. The study uses a broad consent and includes the ability to re-contact participants and share medically actionable results. As part of a partnership with Regeneron Pharmaceuticals, MyCode plans to collect samples from more than 250,000 consented patients, whose de-identified genomic data will help to improve patient care and speed drug discovery and development.